Patent granted in USA
(Thomson Reuters ONE) -
Biotec Pharmacon is pleased to report that one of the company's patent
applications referring to a combination therapy for cancer treatment has been
granted in the U.S. and will be published as US 7,704,973. The patent is a
composition patent protecting combinations of Biotec Pharmacon's proprietary
compound soluble yeast beta-glucan (SBG) as an adjuvant together with monoclonal
antibodies for treatment of cancer. Biotec Pharmacon has developed this concept
together with Memorial Sloan-Kettering Cancer Center (MSKCC). Biotec Pharmacon
and MSKCC are joint owners of this technology and the company has an exclusive
license on MSKCC's rights to this patent. Further patent applications in this
patent family are still pending in other countries.
The granted patent protects a combination of injected anti-cancer antibodies and
oral administered yeast beta glucan. The combination greatly enhanced the
anti-tumor effects against established tumors irrespective of tumor type and
tumor sites in the animal models and gave also promising treatment effects in
patients with neuroblastoma. In addition to patent protection, the favourable
toxicity profile of SBG, combined with the convenience of oral administration,
makes SBG a promising candidate as an adjuvant in cancer therapy.
Svein Lien, Biotec Pharmacon CEO, commented: "We are pleased to secure this
intellectual property as a part of our long terms strategy to develop SBG as an
adjuvant to antibody together with our partner MSKCC in New York. This is an
application we will continue to invest in as we believe that immune stimulation
with SBG has a role to enhance the effect of several types of cancer
treatments."
For further enquiries please contact:
Biotec Pharmacon ASA - Tel: +47 77648900
Svein Lien, CEO
Alexander Bjørnå,
Director IP
About Biotec Pharmacon:
The biopharmaceutical company Biotec Pharmacon develops products for prevention
and treatment of immune related diseases. The company has developed the
bioactive substance SBG (soluble beta glucan), with an aim to treat diabetic
ulcers and inflammatory bowel disease. The company's clinical development
program includes immune therapy of cancer, where combination treatments with SBG
and monoclonal antibodies are being studied in clinical phase I/II. Biotec
Pharmacon also produces non-pharmaceutical health- and diagnostic products and
owns 100% of the marine enzyme company Biotec Marine Biochemicals AS.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1419632]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Amarillo receives updated resource estimate for the Mara Rosa project: 623,000 oz in 11.9MT @ 1.62g/t Gold indicated, and 451,000 oz in 10.2MT @ 1.38g/t Gold inferred , using 0.5g/t cut-off
Datum: 28.05.2010 - 11:55 Uhr
Sprache: Deutsch
News-ID 21639
Anzahl Zeichen: 0
contact information:
Town:
Tromsø
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Patent granted in USA"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
